How can it be that a generic drug—administered off-label in small daily doses and proven to help people suffering from a wide variety of autoimmune diseases and cancers—still languishes in medical obscurity?
Low Dose Naltrexone (LDN) is an active opioid antagonist and works by partially blocking opioid receptors that, in turn, helps to balance your immune system by tricking your body into producing more endorphins. While not for everyone, this generic drug is extremely affordable and presents few known or serious side effects. Administered off-label in small daily doses (0.5 to 4.5 mg), it is being used around the world to help people suffering from a range of ailments including multiple sclerosis, lupus, thyroiditis, inflammatory bowel disease, and various cancers, as well as autism spectrum disorder, chronic fatigue, and depression.
The LDN Book explains the drug’s origins, its primary mechanism, and the latest research from practicing physicians and pharmacists as compiled by Linda Elsegood of The LDN Research Trust, the world’s largest LDN charity organization with more than 19,000 members worldwide. Diagnosed with MS in August of 2000, she started LDN therapy in December of 2003, and now has a better quality of life and hope for the future. She has helped connect thousands of people to this potential remedy to their ailments.
With information from nearly a dozen medical professionals on LDN’s efficacy and two patient-friendly appendices, The LDN Book is a comprehensive resource for doctors, pharmacists, and patients who want to learn more about how LDN is helping people now, and a clarion call for further research that could help millions more.